Blog

ASC 805 Valuation Update: Biopharmaceuticals

Accounting Standard Codification Topic 805 (“ASC 805”), Business Combinations, was designed to provide additional transparency in purchase accounting. The biopharmaceutical industry is a clear beneficiary. With significant contingent payouts, the purchase considerations paid for pre-revenue drug development companies are extremely difficult to assess. Under ASC 805, financial statements provide much better information about the values of future milestone payments and of the distinct clinical candidates acquired. We studied how acquisitions of development stage biopharmaceutical companies were reported in the SEC filings.

View PDF

 

CATEGORIES
LABELS
409A ValuationASC 805ASC 805 Purchase AccountingBusiness InterestsFair Market ValueFair ValueFinancial InstrumentsFinancial ReportingIntangible Asset ValuationIP ValuationLife SciencesPortfolio ValuationPurchase AccountingPurchase Price AllocationTax ComplianceTax ValuationTerm SheetTransactions
RECENT POSTS

More Updates

Navigating SAFE Valuations

Neither “Safe” nor “Simple,” these Simple Agreements for Future Equity are convertible debt instruments that are often misunderstood and hard to value.

May 16, 2024

7 Areas to Transform Your Financial Reporting Valuation

Creating shareholder value is the goal of most for-profit entities, where value is viewed in a strictly financial sense.  In the world of startups and VCs, this means maximizing exit valuations. That exit valuation number is of fundamental importance. Exit valuations are built over time. Thus, tracking valuations is critical.  Companies have many opportunities to track their valuations, from upgraded

February 27, 2024

About Financial Forecast

A financial forecast is a centerpiece of many valuations.  It answers the principal question: “Why the business is valuable in the first place?”  In strategic analysis, financial forecast links business strategy and value.  In financial reporting, a financial forecast is a more refined, post-strategic-planning representation of a company’s expected financial performance. 

December 5, 2023
© 2024 Sorbus Advisors LLC.

Schedule a Call

Most new projects will require a brief introductory conversation. Unless you are a returning client asking for an update to a old valuation, please use the calendar below to schedule a call with us:

Send a Message

We are located in the San Francisco Bay Area, while our clients cover much broader geography, from Southern California to the East Coast and Europe. Please contact us with questions and inquiries. Also, feel free to stop by on your way to the beautiful Sonoma or Napa Valley.

Schedule a Call